Cargando…

Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy

BACKGROUND: The outcome of patients after radiotherapy (RT) for localized prostate cancer in case of prostate-specific antigen (PSA) progression during primary hormonal therapy (HT) is not well known. METHODS: A group of 27 patients presenting with PSA progression during primary HT for local prostat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pinkawa, Michael, Piroth, Marc D, Holy, Richard, Djukic, Victoria, Klotz, Jens, Pfister, David, Heidenreich, Axel, Eble, Michael J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551819/ https://www.ncbi.nlm.nih.gov/pubmed/23227960 http://dx.doi.org/10.1186/1748-717X-7-209

Ejemplares similares

Self-assessed bowel toxicity after external beam radiotherapy for prostate cancer - predictive factors on irritative symptoms, incontinence and rectal bleeding
por: Pinkawa, Michael, et al.
Publicado: (2009)

Dose-escalation using intensity-modulated radiotherapy for prostate cancer - evaluation of quality of life with and without (18)F-choline PET-CT detected simultaneous integrated boost
por: Pinkawa, Michael, et al.
Publicado: (2012)

Consequential late effects after radiotherapy for prostate cancer - a prospective longitudinal quality of life study
por: Pinkawa, Michael, et al.
Publicado: (2010)

Impact of age and comorbidities on health-related quality of life for patients with prostate cancer: evaluation before a curative treatment
por: Pinkawa, Michael, et al.
Publicado: (2009)

Quality of life more than 10 years after radiotherapy for localized prostate cancer—impact of time after treatment and prescription dose
por: Pinkawa, Michael, et al.
Publicado: (2020)

Long-term prognostic significance of rising PSA levels following radiotherapy for localized prostate cancer – focus on overall survival
por: Freiberger, Carla, et al.
Publicado: (2017)

Sequencing chemotherapy and radiotherapy in locoregional advanced breast cancer patients after mastectomy – a retrospective analysis
por: Piroth, Marc D, et al.
Publicado: (2008)

Gastrointestinal Quality-of-Life Trajectories after Radiotherapy for Prostate Cancer—Which Patients Suffer from Persisting Problems?
por: Pinkawa, Michael
Publicado: (2023)

Treatment of Locally Advanced Prostate Cancer: A Case Report and Narrative Review
por: Peinemann, Frank, et al.
Publicado: (2012)

Interdisciplinary consensus statement on indication and application of a hydrogel spacer for prostate radiotherapy based on experience in more than 250 patients
por: Müller, Arndt-Christian, et al.
Publicado: (2016)

Toxicity of dose-escalated radiotherapy up to 84 Gy for prostate cancer
por: Rosenbrock, Johannes, et al.
Publicado: (2023)

Radiotherapy for hormone-sensitive prostate cancer with synchronous low burden of distant metastases
por: Müller, Arndt-Christian, et al.
Publicado: (2022)

Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme - a dosimetric comparison
por: Piroth, Marc D, et al.
Publicado: (2009)

Ano-rectal wall dose-surface maps localize the dosimetric benefit of hydrogel rectum spacers in prostate cancer radiotherapy
por: Vanneste, Ben G.L., et al.
Publicado: (2018)

Sequential (gemcitabine/vinorelbine) and concurrent (gemcitabine) radiochemotherapy with FDG-PET-based target volume definition in locally advanced non-small cell lung cancer: first results of a phase I/II study
por: Gagel, Bernd, et al.
Publicado: (2007)

Radiotherapy in nodal oligorecurrent prostate cancer
por: Pinkawa, Michael, et al.
Publicado: (2021)

Relapse patterns after radiochemotherapy of glioblastoma with FET PET-guided boost irradiation and simulation to optimize radiation target volume
por: Piroth, Marc D., et al.
Publicado: (2016)

Normalization of prostate specific antigen in patients treated with intensity modulated radiotherapy for clinically localized prostate cancer
por: Schmitz, Matthew D, et al.
Publicado: (2010)

Absorbable hydrogel spacer use in men undergoing prostate cancer radiotherapy: 12 month toxicity and proctoscopy results of a prospective multicenter phase II trial
por: Uhl, Matthias, et al.
Publicado: (2014)

Oligometastatic prostate cancer: definition and the role of local and systemic therapy: a narrative review
por: Mahjoub, Samy, et al.
Publicado: (2021)

Prostate-specific antigen kinetics after stereotactic body radiotherapy as monotherapy or boost after whole pelvic radiotherapy for localized prostate cancer
por: Kim, Hun Jung, et al.
Publicado: (2015)

Prostate radiotherapy for metastatic hormone sensitive prostate cancer—myth or reality?
por: Onal, Cem
Publicado: (2019)

[(18)F] fluoromisonidazole and [(18)F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study
por: Gagel, Bernd, et al.
Publicado: (2006)

Radical retropubic and perineal prostatectomy for clinically localised prostate cancer in renal transplant recipients
por: Heidenreich, Axel, et al.
Publicado: (2014)

Dose-Escalated Salvage Radiotherapy for Macroscopic Local Recurrence of Prostate Cancer in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era
por: Tamihardja, Jörg, et al.
Publicado: (2022)

Ultrahypofractionation of localized prostate cancer: Statement from the DEGRO working group prostate cancer
por: Wolf, Frank, et al.
Publicado: (2020)

Kinetics of Prostate-Specific Antigen after Carbon Ion Radiotherapy for Prostate Cancer
por: Darwis, Narisa Dewi Maulany, et al.
Publicado: (2020)

Clinical Outcomes from Dose-Reduced Radiotherapy to the Prostate in Elderly Patients with Localized Prostate Cancer
por: Samson, Nina, et al.
Publicado: (2021)

The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer.
por: Fosså, S. D., et al.
Publicado: (1992)

Dose Distribution of High Dose-Rate and Low Dose-Rate Prostate Brachytherapy at Different Intervals—Impact of a Hydrogel Spacer and Prostate Volume
por: Haddad, Hathal, et al.
Publicado: (2023)

Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer
por: Phak, Jeong Hoon, et al.
Publicado: (2016)

External beam radiotherapy for localized prostate cancer
por: Yilmaz, Hasan, et al.
Publicado: (2015)

Validation and implementation of a mobile app decision support system for prostate cancer to improve quality of tumor boards
por: Ural, Yasemin, et al.
Publicado: (2023)

Association of the Placement of a Perirectal Hydrogel Spacer With the Clinical Outcomes of Men Receiving Radiotherapy for Prostate Cancer: A Systematic Review and Meta-analysis
por: Miller, Larry E., et al.
Publicado: (2020)

Radiotherapy combined with hormonal therapy in prostate cancer: the state of the art
por: Milecki, Piotr, et al.
Publicado: (2010)

Study of prostate-specific antigen levels during salvage radiotherapy after prostate cancer surgery
por: Aizawa, Takuya, et al.
Publicado: (2023)

Postoperative radiotherapy for prostate cancer: Morbidity of local-only or local-plus-pelvic radiotherapy
por: Waldstein, Cora, et al.
Publicado: (2017)

Complications following surgery with or without radiotherapy or radiotherapy alone for prostate cancer
por: Wallis, C J D, et al.
Publicado: (2015)

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis
por: Burdett, Sarah, et al.
Publicado: (2019)

The role of radiotherapy in localised and locally advanced prostate cancer
por: Bolla, Michel, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sp7aj02sunndtsvfccecnlqhcp